Phillip Md Et Al Frost Purchases 80,000 Shares of Opko Health, Inc. (OPK) Stock

Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 80,000 shares of the stock in a transaction on Friday, September 15th. The stock was purchased at an average cost of $6.01 per share, with a total value of $480,800.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at $18,444,395.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, September 18th, Phillip Md Et Al Frost purchased 40,000 shares of Opko Health stock. The stock was bought at an average cost of $6.00 per share, with a total value of $240,000.00.
  • On Thursday, September 14th, Phillip Md Et Al Frost purchased 260,000 shares of Opko Health stock. The stock was bought at an average cost of $5.98 per share, with a total value of $1,554,800.00.
  • On Friday, August 25th, Phillip Md Et Al Frost purchased 25,000 shares of Opko Health stock. The stock was bought at an average cost of $6.17 per share, with a total value of $154,250.00.
  • On Thursday, August 24th, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The stock was bought at an average cost of $6.24 per share, with a total value of $62,400.00.
  • On Wednesday, August 23rd, Phillip Md Et Al Frost purchased 12,000 shares of Opko Health stock. The stock was bought at an average cost of $6.13 per share, with a total value of $73,560.00.
  • On Tuesday, August 22nd, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The stock was bought at an average cost of $6.13 per share, with a total value of $11,034.00.
  • On Monday, August 21st, Phillip Md Et Al Frost purchased 25,000 shares of Opko Health stock. The stock was bought at an average cost of $6.10 per share, with a total value of $152,500.00.
  • On Thursday, August 17th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The stock was bought at an average cost of $5.96 per share, with a total value of $298,000.00.
  • On Wednesday, August 16th, Phillip Md Et Al Frost purchased 40,000 shares of Opko Health stock. The stock was bought at an average cost of $6.04 per share, with a total value of $241,600.00.
  • On Tuesday, August 15th, Phillip Md Et Al Frost purchased 25,000 shares of Opko Health stock. The stock was bought at an average cost of $6.08 per share, with a total value of $152,000.00.

Shares of Opko Health, Inc. (OPK) opened at 6.01 on Wednesday. The company’s 50 day moving average price is $6.19 and its 200 day moving average price is $6.84. Opko Health, Inc. has a 12 month low of $5.85 and a 12 month high of $12.15. The company’s market cap is $3.36 billion.

Opko Health (NASDAQ:OPK) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The firm had revenue of $314.20 million for the quarter, compared to the consensus estimate of $322.64 million. During the same quarter in the previous year, the business earned $0.02 earnings per share. The company’s quarterly revenue was down 12.0% on a year-over-year basis. On average, equities analysts expect that Opko Health, Inc. will post ($0.19) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/09/20/phillip-md-et-al-frost-purchases-80000-shares-of-opko-health-inc-opk-stock.html.

Large investors have recently made changes to their positions in the stock. Timber Hill LLC purchased a new position in Opko Health during the 1st quarter valued at about $114,000. World Asset Management Inc grew its holdings in shares of Opko Health by 23.6% during the 1st quarter. World Asset Management Inc now owns 15,176 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 2,900 shares during the period. Financial Architects Inc grew its holdings in shares of Opko Health by 45.0% during the 2nd quarter. Financial Architects Inc now owns 15,460 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 4,800 shares during the period. Envestnet Asset Management Inc. grew its holdings in shares of Opko Health by 6.5% during the 1st quarter. Envestnet Asset Management Inc. now owns 16,356 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 1,001 shares during the period. Finally, Blair William & Co. IL purchased a new position in shares of Opko Health during the 2nd quarter worth approximately $112,000. Institutional investors own 22.46% of the company’s stock.

Several brokerages have recently weighed in on OPK. Jefferies Group LLC reissued a “hold” rating and issued a $8.00 price target on shares of Opko Health in a research note on Monday, June 12th. Zacks Investment Research raised Opko Health from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a research note on Friday, July 21st. J P Morgan Chase & Co cut Opko Health from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $12.00 to $7.00 in a research note on Thursday, September 14th. Barrington Research increased their price target on Opko Health to $11.00 and gave the company an “outperform” rating in a research note on Tuesday, July 18th. Finally, Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $19.50 price target on shares of Opko Health in a research note on Tuesday, June 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $14.36.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply